AMCP Virtual Legislative Days 2020; AMCP Sends Letter to HHS Secretary Azar on Anti-Kickback Rules Concerns; HHS Authorizes Pharmacists to Administer COVID-19 Vaccine; AMCP Submits Comments on COVID-19 Vaccine Allocation Framework; CMS Issues Proposed Rule Establishing a New Coverage Pathway for Breakthrough Devices; CMS Issues Rule Limiting Pharmacist-Administered COVID-19 Testing; President Trump Signs Drug Pricing Executive Order.
CMS Issues Request for Information on Electronic Prescribing of Controlled Substances; President Trump Signed Executive Orders on Drug Pricing; AMCP Submits Comments on Medicaid Drug Rebate Program Proposed Rule; House of Representatives Holds COVID-19 Vaccine and Coronavirus Response Hearings.
CMS Issues Proposed Rule Updating the Medicaid Drug Rebate Program; SAMHSA Publishes Final Rule Amending Substance Use Disorder Treatment Records Privacy; AMCP Joins Pharmacy Stakeholder Letter on Vaccine Administration; AMCP Signs Joint Comment Letter on Pharmacy Telehealth in Medicare.
On November 2, AMCP submitted comments on CMS’s Third Interim Final Rule responding to the COVID-19 emergency, thanking the agency for granting pharmacists the authority to order COVID-19 diagnostic tests for Medicare beneficiaries and expressing concern about the agency’s new guidance which would limit COVID-19 diagnostic tests without an order.
On November 2, AMCP submitted comments on a CMS Medicare Coverage of Innovative Technology proposed rule establishing a national coverage pathway for innovative devices authorized under FDA’s Breakthrough Devices Program and clarifying the agency’s definition of “reasonable and necessary”. AMCP called on CMS to indicate how digital therapeutics (DTx) will fit into Medicare’s coverage and payment framework in its Final Rule.